Postponed clinical trials affect ALK finances – central phase III trials have been delayed

The Monday guidance upgrade from allergy company ALK, which was confirmed on Wednesday morning, especially happened because sales had been better than expected, but also due to a series of savings and necessary postponements of clinical trials, such as the crucial Chinese phase III trial, which was meant to start in August, explains CEO Carsten Hellmann.
ALK CEO Carsten Hellmann | Photo: Gregers Tycho/Ritzau/Ritzau Scanpix
ALK CEO Carsten Hellmann | Photo: Gregers Tycho/Ritzau/Ritzau Scanpix
BY ALBERT RØNNING-ANDERSSON, TRANSLATED BY NIELSINE NIELSEN

Monday afternoon, Danish allergy company ALK upgraded the guidance for its main figures relating to revenue and earnings ahead of today's presentation of the firm's quarterly report.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading